Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California. more
Time Frame | ORIC | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2.04% | 0.67% | 0.49% |
1-Month Return | 1.27% | 0.26% | 5.96% |
3-Month Return | -4.67% | -6.21% | 9.35% |
6-Month Return | 9.34% | 1.69% | 14.4% |
1-Year Return | 13.61% | 11.41% | 32.23% |
3-Year Return | -31.96% | 12.87% | 33.15% |
5-Year Return | -62.75% | 48.89% | 95.23% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 1.00M | 970.00K | 897.00K | 966.00K | 1.03M | [{"date":"2019-12-31","value":96.9,"profit":true},{"date":"2020-12-31","value":93.99,"profit":true},{"date":"2021-12-31","value":86.92,"profit":true},{"date":"2022-12-31","value":93.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (1.00M) | (970.00K) | (897.00K) | (966.00K) | (1.03M) | [{"date":"2019-12-31","value":-100000000,"profit":false},{"date":"2020-12-31","value":-97000000,"profit":false},{"date":"2021-12-31","value":-89700000,"profit":false},{"date":"2022-12-31","value":-96600000,"profit":false},{"date":"2023-12-31","value":-103200000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 28.57M | 49.34M | 78.87M | 86.77M | 110.78M | [{"date":"2019-12-31","value":25.79,"profit":true},{"date":"2020-12-31","value":44.54,"profit":true},{"date":"2021-12-31","value":71.2,"profit":true},{"date":"2022-12-31","value":78.32,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (28.57M) | (74.19M) | (78.87M) | (91.77M) | (110.78M) | [{"date":"2019-12-31","value":-2856900000,"profit":false},{"date":"2020-12-31","value":-7418600000,"profit":false},{"date":"2021-12-31","value":-7887100000,"profit":false},{"date":"2022-12-31","value":-9176700000,"profit":false},{"date":"2023-12-31","value":-11078000000,"profit":false}] |
Total Non-Operating Income/Expense | 3.08M | 789.00K | 297.00K | 5.29M | - | [{"date":"2019-12-31","value":58.28,"profit":true},{"date":"2020-12-31","value":14.91,"profit":true},{"date":"2021-12-31","value":5.61,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (26.88M) | (73.70M) | (78.72M) | (89.12M) | (100.70M) | [{"date":"2019-12-31","value":-2688300000,"profit":false},{"date":"2020-12-31","value":-7370300000,"profit":false},{"date":"2021-12-31","value":-7871500000,"profit":false},{"date":"2022-12-31","value":-8912200000,"profit":false},{"date":"2023-12-31","value":-10069700000,"profit":false}] |
Income Taxes | (1.40M) | 23.57M | (1.04M) | 2.35M | - | [{"date":"2019-12-31","value":-5.93,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-4.4,"profit":false},{"date":"2022-12-31","value":9.99,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (25.49M) | (97.27M) | (77.68M) | (91.48M) | - | [{"date":"2019-12-31","value":-2548600000,"profit":false},{"date":"2020-12-31","value":-9727000000,"profit":false},{"date":"2021-12-31","value":-7767700000,"profit":false},{"date":"2022-12-31","value":-9147700000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (26.88M) | (73.70M) | (78.72M) | (89.12M) | (100.70M) | [{"date":"2019-12-31","value":-2688300000,"profit":false},{"date":"2020-12-31","value":-7370300000,"profit":false},{"date":"2021-12-31","value":-7871500000,"profit":false},{"date":"2022-12-31","value":-8912200000,"profit":false},{"date":"2023-12-31","value":-10069700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (25.49M) | (97.27M) | (77.68M) | (91.48M) | (100.70M) | [{"date":"2019-12-31","value":-2548600000,"profit":false},{"date":"2020-12-31","value":-9727000000,"profit":false},{"date":"2021-12-31","value":-7767700000,"profit":false},{"date":"2022-12-31","value":-9147700000,"profit":false},{"date":"2023-12-31","value":-10069700000,"profit":false}] |
EPS (Diluted) | (0.08) | (6.22) | (2.07) | (2.25) | (1.96) | [{"date":"2019-12-31","value":-8,"profit":false},{"date":"2020-12-31","value":-622,"profit":false},{"date":"2021-12-31","value":-207,"profit":false},{"date":"2022-12-31","value":-225,"profit":false},{"date":"2023-12-31","value":-196,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ORIC | |
---|---|
Cash Ratio | 12.82 |
Current Ratio | 13.15 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ORIC | |
---|---|
ROA (LTM) | -29.22% |
ROE (LTM) | -45.98% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ORIC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.09 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.91 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ORIC | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 2.55 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.13 |
Oric Pharmaceuticals Inc (ORIC) share price today is $9.6
Yes, Indians can buy shares of Oric Pharmaceuticals Inc (ORIC) on Vested. To buy Oric Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ORIC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Oric Pharmaceuticals Inc (ORIC) via the Vested app. You can start investing in Oric Pharmaceuticals Inc (ORIC) with a minimum investment of $1.
You can invest in shares of Oric Pharmaceuticals Inc (ORIC) via Vested in three simple steps:
The 52-week high price of Oric Pharmaceuticals Inc (ORIC) is $16.65. The 52-week low price of Oric Pharmaceuticals Inc (ORIC) is $6.33.
The price-to-earnings (P/E) ratio of Oric Pharmaceuticals Inc (ORIC) is
The price-to-book (P/B) ratio of Oric Pharmaceuticals Inc (ORIC) is 2.55
The dividend yield of Oric Pharmaceuticals Inc (ORIC) is 0.00%
The market capitalization of Oric Pharmaceuticals Inc (ORIC) is $703.55M
The stock symbol (or ticker) of Oric Pharmaceuticals Inc is ORIC